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Abstract. Fas-associated factor 1 (Faf1) has been
described as a Fas-binding pro-apoptotic protein and
as a component of the death-inducing signaling
complex (DISC) in Fas-mediated apoptosis. Faf1 is
able to potentiate Fas-induced apoptosis in several cell
lines, although its specific functions are still not clear.
Here we show that Faf1 is highly expressed in several
areas of the developing telencephalon. Its expression
pattern appears to be dynamic at different embryonic
stages and to be progressively confined within limited
territories. To decipher the specific role of Faf1 in
developing brain, we used cDNA over-expression and
mRNA down-regulation experiments to modulate
Faf1 expression in telencephalic neural precursor
cells, and we showed that in neural cell death Faf1
acts as a Fas-independent apoptotic enhancer. More-
over, we found that Faf1 protein level is down-
regulated during apoptosis in a caspase- and Apaf1-
dependent manner.
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Introduction
Fas-associated factor 1 (Faf1) was introduced, origi-
nally in mouse, as a novel Fas/CD95 interacting
protein: when transiently over-expressed in L-cells,
it potentiates the apoptotic signal generated through
Fas [1]. FAF1 has also been cloned from a human
HeLa cDNA library and it shows all the characteristics
so far described for the murine and avian Faf1 [2].
Unlike murine Faf1, human FAF1 initiates apoptosis
in BOSC23 cells in the absence of any extrinsic death
signals, and the apoptotic potential does not require
the Fas-binding domain [3, 4]. Subsequently, Faf1 has
been demonstrated to be a component of the death-
inducing signaling complex (DISC) in Fas-mediated
apoptosis, although it does not contain typical death
motifs such as the death domain (DD), the death
effector domain (DED) or the caspase recruitment
domain (CARD) [5]. Moreover, recently, Faf1 has
been implicated in chemotherapeutic-induced apop-
tosis via the death effector filament (DEF) assembly
[6]. It is noteworthy that Faf1 contains a novel nuclear
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localization sequence (NLS) and has been previously
found to localize in the nucleus [2]. In addition to
interacting with Fas/CD95, Faf1 has also been identi-
fied as an interaction partner of the RelA (p65)
subunit of NF-kB, thus preventing its translocation to
the nucleus. It was postulated that the combined
action of Faf1 in the Fas-DISC and in the down-
regulation of NF-kB might enhance the efficacy of
receptor-mediated cell death [7]. Although Faf1
seems to have multiple functions related to apoptosis,
it has also been described as being involved in the
ubiquitin-proteasome pathway, playing a role as a
scaffolding protein and regulating the degradation of
multiubiquinated proteins [8].
Apoptosis has also been recognized as being an
important event in the normal development of the
mammalian nervous system, where it appears to be
fundamental for the control of the final numbers of
neurons and glia cells (reviewed in [9–13]). The
delicate balance between cell proliferation and cell
death of neural precursor cells determines the size and
shape of the nervous system [13]. Neural precursor
cell death is mainly mediated by the apoptosome, a
multimolecular complex whose core is the adapter
protein Apaf1 [14]. Activation of the apoptosome
depends on cytochrome c release from mitochondria,
which act as sensors of neurodevelopmental apoptotic
stimuli. In this work, we analyzed the specific involve-
ment of Faf1 in neurodevelopment by means of the
heterozygous Faf1 gene trap (gt) mouse strain (Faf1+/
gt) and by a proneural cell line generated in our
laboratory (Embryonic telencephalic nave Apaf1
cells, ETNA). This cell line derives from the brain
primordia isolated from wild-type embryos at embry-
onic stage (e) 14 (referred as control ETNA cells) or
from e14 Apaf1–/– embryos that lack the Apaf1 gene
and therefore are impaired in apoptosome formation
(referred as ETNA–/– cells) [15]. Despite the fact that
Faf1 is widely expressed in many adult and embryonic
tissues and in tumor cell lines [2, 3], we found that it is
predominantly expressed in specific areas of mouse
brain at various embryonic stages. To elucidate the
role of Faf1 in neurodevelopment, we induced cell
death in cortical explants from embryos with Faf1
haploinsufficiency and we modulated Faf1 expression
in the neural embryonic ETNA cells. In both cases, we
observed its involvement in neural cell death as an
apoptotic enhancer.Moreover, we found that the Faf1
protein is degraded during apoptosis via apoptosome
formation and caspase activation.
Materials and methods
Plasmid constructs. Faf1-myc fusion protein expres-
sion vector was created by PCR cloning of Faf1 cDNA
(NM_007983) between the BamHI and EcoRV sites
of pcDNA/3.1myc-His (Invitrogen, Carlsbad, CA).
Faf1 cDNA was amplified from a murine cDNA
library using the following primers: 5-GTATG-
GATCCACCATGGCGTCCAACATG-3 and 5-
GTTTGATATCCTCTTTTGCTTGAAGGAA-3.
Four cleavage-site mutants of Faf1 (pcDNA3.1-Faf1-
D151N, -D294N, -D297N and D496N) were made by
mutating Asp151, Asp294, Asp297 and Asp496 into
Asn151, Asn294, Asn297 and Asn496 by site-directed
mutagenesis (Stratagene, Cedar Creek, CA) accord-
ing to the manufacturers instructions. Stable trans-
fection of Faf1 interference RNA constructs was
carried out as previously reported by [16].
Mouse stocks and manipulation. The generation of
Faf1+/gtmice was performed by the gene trap method-
ology [17]. The integration of the IRESbgeo reporter
vector, containing a splice-acceptor site upstream of
the b-galactosidase (LacZ) and the neomycin resist-
ance (neo) genes [18], occurred within the Faf1 locus
downstream of its functional promoter. The embryos
were taken from timedmatings and the day onwhich a
vaginal plug was detected was designated as e0.5.
Pregnant Faf1+/gt females were killed by cervical
dislocation and the embryos were dissected and
fixed in 4% paraformaldehyde (PFA). The embryos
or mice were genotyped from extra-embryonic mem-
branes or from tail biopsies.
RNA in situ hybridization and staining for b-galacto-
sidase activity. RNA in situ hybridization and prepa-
ration of the DIG-labeled antisense and sense Faf1
probes were performed as described by the manufac-
turer (RocheApplied Science,Mannheim,Germany).
Whole mountLacZ staining of Faf1+/gt embryos [from
e10.5 to postnatal stage (pn) 9] was carried out as
described in [19]. After staining, the embryos were
embedded in paraffin and serial sectioned for histo-
logical analysis. Photographswere taken using aZeiss-
Axioskop microscope.
RNA extraction and Northern analysis. Total RNA
was isolated using TRIzol reagent (Invitrogen) ac-
cording to themanufacturers instructions.Aliquots of
10 mg were separated on 1% agarose gels containing
2.2 M formaldehyde in 1MOPS buffer [20 mM3-(N-
morpholino) propanesulfonic acid, 8 mM sodium
acetate, 1 mM EDTA, pH 7.0] and transferred to a
nylon membrane (Gene Screen Plus, Perkin Elmer
Life Science Inc., Waltham, MA) in phosphate buffer
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Figure 1. Fas-associated factor 1 (Faf1) expression pattern. (A–H) LacZ staining was performed on 4% paraformaldehyde fixed Faf1+/gt
embryos at embryonic stage (e) 10.5, 11.5, 12.5, 13.5, 14.5, and brains at e17.5 and postnatal stage (pn) 9. (A–F) A lateral view; (G) dorsal
and ventral brain views; and (H) a view of cross-sectioned brain. The arrows point to the blue staining regions of optic cup (oc) (A–D),
olfactory bulbs (ob) (E), hippocampus (hi) and hypothalamus (hy) (H). (I) Whole mount in situmRNA hybridization was carried out on
wild-type embryos at e10.5 (left side). The 300-bp fragment of Faf1 mRNA was used as DIG-labeled probe. X-gal staining of Faf1+/gt
embryos of the same age (e10.5) is shown on the right side. The arrows point to the overlapped regions of staining. Black and white images
are shown in order to allow better comparison between the two techniques used in this context. (J) LacZ staining on e10.5Faf1+/gt embryos
was performed. After staining, the embryos were embedded in paraffin and transverse sections were cut with a Vibratome. d,
diencephalon; Fb, forebrain; fv, fourth ventricle; Hb, hindbrain; hi, hippocampus; hne, hippocampal neuroepithelium; hy, hypothalamus;
lv, lateral ventricle; Mb, midbrain; ob, olfactory bulbs; oc, optic cup; oe, olfactory epithelium; or, optic recess; tv, third ventricle; tvw,
telencephalic vesicle wall. (K) Expression level of Faf1 mRNAwas detected by quantitative real-time PCR in brain, stomach, heart, gut,
liver, kidney and lung of wild-type littermates at pn1. mRNA level was normalized to GAPDHmRNA, used as control. (L) Western blot
analysis of Faf1 in total protein extracts of the indicated tissues fromwild- typemice at pn1. Anti-GAPDHantibodywas used as control of
equal loading. (M) Western blot analysis of Faf1 in total protein extracts of brains from wild-type 6-month-old mice (A1, A2 and A3) and
e15.0 embryos (E1, E2 and E3). Anti-b-tubulin antibody was used as a control of equal loading.
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by electroblotting. The probes for Faf1 cDNA and for
actin were labeled with [32P]dCTP using the random
priming labeling kit (Amersham, Buckinghamshire,
UK). Hybridizations were carried out using Expres-
sHyb solution (Becton Dickinson, Franklin Lakes,
NJ).
Quantitative real-time PCR. Total RNAwas isolated
using TRIzol reagent (Invitrogen) and cDNA was
synthesized using the SuperScript double-stranded
cDNA Synthesis System (Invitrogen). Synthesized
cDNA (100 ng) was PCR-amplified. Primers used for
qRT-PCR were: Faf1 forward 5-GTGACTTTG-
GAGGTGAGACCA-3 and Faf1 reverse 5-
TTCCACGTCTCCAGTCTTCC-3; GAPDH for-
ward 5-GTGGCAAAGTGGAGATTGTTGCC-3
and GAPDH reverse 5-GATGAT-
GACCCGTTTGGCTCC-3; actin forward 5-
CTCATTGCCGATAGTGATGACC-3 and actin re-
verse 5-AGCAAGAGAGGCATCCTGACC-3.
RNA quantification was performed by qRT-PCR in
ABI PRISM 7000 Sequence Detection System (Ap-
plied Biosystems, Foster City, CA). Delta-delta Ct
values were normalized with those obtained from the
amplification of GAPDH and actin cDNAs. All
reactions were performed in triplicate.
Cell cultures and transfections. ETNA cells were
obtained as described in [15]. They were routinely
grown in DMEM + 10% FCS, at 338C (permissive
temperature for large T antigen expression) in an
atmosphere of 5% CO2 in air, and used between
passages 2 and 7. Stable expression of vector (1 mg
DNA/5105–7105 cells) was obtained with Lipofect-
amine2000 (Invitrogen) according to the manufactur-
ers instructions. For the selection of stable transfected
clones, 150 ng of the plasmid containing hygromycin
resistance was transfected concomitantly with expres-
sion vector. After 3 h of incubation with transfection
reagents, the cells were cultured in normal growth
medium for the indicated period of time and 200 mg/ml
hygromycin (Gibco, Carlsbad, CA) was added to the
medium for the selection of resistant clones. Transient
siRNA transfection was performed with two 19-
nucleotide siRNA duplex directed against two Faf1
mRNA sequences, 5-UGACUGCCAUCCU-
GUAUUU-3 and 5-CCAUCAGACUCUCCUUA-
GA-3 (siFaf1) (Dharmacon RNA technologies, La-
fayette, CO), and with the silencer GAPDH siRNA
(Ambion, Foster City, CA). Control cells were trans-
fected with a scrambled siRNA duplex (Ambion),
which does not present homology with any other
murine mRNAs. Cells were transfected by Lipofect-
amine2000 according to the manufacturers instruc-
tions and total RNA was collected after 24 h of
transfection. Transfection efficiency of siRNA into
ETNAcells was estimated by transfecting fluorescein-
conjugated oligonucleotides (Ambion) and found to
be >80%.
Cell treatments. ETNA cells were treated with
apoptotic stimulus staurosporine (STS; Gibco) at
concentration of 5 mM for 6, 19 and 24 h and cisplatin
(CDDP; Sigma, St. Louis, MO) at concentration of
10 mM for 48 h. ETNA cells were treated with cyclo-
heximide (Sigma) at concentration of 10, 20 and 50 mg/
ml for 24 and 48 h. ETNA cells were induced by anti-
Fas antibody (Upstate CH11, Billerica, MA), which
mimics Fas-ligand, at concentration of 1 mg/ml for
48 h.
Ex vivo embryonic mouse brain culture and apoptosis
induction. The procedure for culturing embryonic
mouse brain slices was adapted from [20]. In brief,
pregnant mice were killed by cervical dislocation at
e12.5. The embryoswere removed from the uterus and
placed in a fresh dish of cold PBS. The embryos were
then decapitated and the brain was removed and
placed in a fresh dissection dish. The cerebellum was
used for DNA extraction and successive genotyping.
The cortices were quickly dissected and rinsed briefly
in ice-cold HBSS (Gibco), supplemented with 25 mM
HEPES, pH 7.2, and 6.5 mg/ml glucose. The cortices
were then plated onto 30-mm Millicell pore filters
(Millipore, Billerica,MA) in a 12-well plate. Eachwell
contained 0.8 ml medium (25% horse serum, 50%
Eagles basal medium, 25% HBSS, 5 mg/ml glucose,
50 U/ml penicillin, 50 mg/ml streptomycin). Apoptosis
was induced with STS (final concentration 10 mM).
After culturing cortices for the desired period of time,
individual cortices were lifted from the well and lysed
in 100 ml lysis buffer (20 mM Tris-HCl, 1% Triton X-
100, 150 mM NaCl, 1 mM EDTA, 5 mM MgCl2)
containing 1 mM PMSF and a protease inhibitor
cocktail (Sigma).
Western blotting and caspase-3 activity assay. After
rinsing the cultures with ice-cold PBS, cell lysis was
performed in lysis buffer (20 mM Tris-HCl, 1%
Triton X-100, 150 mM NaCl, 1 mM EDTA, 5 mM
MgCl2) containing 1 mM PMSF and a protease
inhibitor cocktail (Sigma). A clear supernatant was
obtained by centrifugation of lysates at 17 000 g for
10 min.Alternatively, to obtain nuclear extracts, cells
were collected and incubated with “nucleus buffer”
(1 mM K2HPO4, 5 mM MgCl2, 150 mM NaCl, 1 mM
EGTA, 0.1 mMDTT, 0.3%Triton X-100, pH 6.4) for
30 min at 48C, then centrifuged at 450 g for 10 min to
isolate nuclei (pellet) from cytosolic fraction (super-
natant). Pellet was finally lysed in RIPA buffer
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(50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40,
12 mM sodium deoxycholate). Protein content was
determined using Bradford protein assay (Bio-Rad,
Hercules, CA). Western blots were performed on
polyvinylidene difluoride membranes (Immobilon P,
Millipore). Faf1 was detected with a goat polyclonal
anti-Faf1 antibody (clone M-20, Santa Cruz Biotech-
nology, Santa Cruz, CA) and was used at concen-
tration of 1:500. Pax6 was detected with a mouse
monoclonal anti-Pax6 antibody (BabCO) at concen-
tration of 1:1000. SOD1 was detected with a rabbit
polyclonal anti-SOD1 antibody (Santa Cruz Bio-
technology) at concentration of 1:1000. Both full-
length and cleaved active fragments of caspase-3
were detected by using a rabbit polyclonal anti-
caspase-3 antibody at concentration of 1:1000 (Cell
Signaling, Danvers, MA). Both full-length and
cleaved PARP were detected by a rabbit polyclonal
anti-PARP antibody at concentration of 1:1000 (Cell
Signaling). Anti-b-actin (clone AC15) and anti-
GAPDH antibodies were purchased from Sigma
(1:1000 diluted). Caspase-3 activity was assayed by
incubating equal amounts (30 mg) of clear cell lysates
with 20 mM Ac-DEVD-AMC (Calbiochem, San
Diego, CA) in lysis buffer for 30 min at 378C. The
amount of 7-amido-4-methylcoumarin (AMC; Cal-
biochem) release was quantified using a fluorescence
plate reader, as described in [15].
Data presentation. All experiments were performed
at least three different times, unless otherwise indi-
cated. Data are expressed as the means  SD and
significance was assessed by Students t-test. Differ-
ences with p values <0.05 were considered as signifi-
cant.
Results
Faf1 expression in the developing nervous system.
Using the gene trap methodology, we generated the
Faf1+/gt mouse strain (see Materials and methods).
Faf1 mutation in homozygous condition is lethal
around the two-cell stage [21]. Next, we have inves-
tigated Faf1 expression pattern by studying LacZ
activity in viable and normal Faf1+/gt mice, since the
reporter vector was integrated downstream of Faf1
functional promoter.
First, we confirmed the reduction of Faf1 mRNA and
protein inFaf1+/gt vs wild-type littermates byNorthern
and Western blot analysis (Fig. 4E and data not
shown). We then monitored Faf1 expression visualiz-
ingLacZ activity in whole-mount and in sections from
embryos bymeans of theb-galactosidase chromogenic
substrate X-galactose (X-gal) (Fig. 1A–H, J). X-gal
staining showed that the Faf1+/gt mouse strain dis-
played a strong expression pattern of Faf1 gene in the
dorsal telencephalon, the diencephalon and the optic
cup (Fig. 1A–H). Throughout e10.5–e11.5 (Fig. 1A,
B), LacZ activity is localized within the telencephalic
hemispheres and along the optic stalk, as visible in the
transverse sections shown in Figure 1J.
The localization of blue staining at e12.5 and e13.5 is
limited to the same areas and, in particular, is shown
within the eye and the olfactory bulbs (Fig. 1C–E).
Later in development (e17.5 and postnatal brain),
Faf1 expression is progressively restricted in defined
regions of the forebrain, such as the hippocampus and
the hypothalamus (Fig. 1G, H).
Histological examination of sectioned embryos pro-
vided us with a more detailed visualization of LacZ
activity. Specific Faf1 expression is observed at e10.5
within developing neocortex, hippocampal neuroepi-
thelium, optic recess and diencephalon (Fig. 1J).
To confirm results obtained through X-gal method-
ology, we carried out in situ mRNA hybridization on
whole embryos at e10.5 where we observed Faf1-
specific expression in the same brain regions (Fig. 1I)
with a more extended distribution of themRNAwhen
compared with the X-gal staining. Furthermore, we
estimated Faf1 mRNA and protein level in various
mouse embryonic tissues at pn1 by quantitative real-
time PCR and by Western blot, so confirming a
predominant Faf1 expression at the brain level
(Fig. 1K, L); we also verified whether Faf1 expression
was restricted in developing brain, by comparing Faf1
protein levels between embryonic (e15.0) and adult
brain (Fig. 1M).
Faf1 over-expression in telencephalic neural precursor
cells increases cell death after apoptotic stimuli. To
gain an understanding of the role of Faf1 in developing
brain, we took advantage of the embryonic neural
ETNA cells that were established from the brain
primordia isolated from e14 wild-type embryos [15].
We transfected ETNA cells with the murine Faf1
cDNA cloned in the mammalian expressing vector
pcDNA3.1/myc-his and we selected some clones
(referred as clones 22, 44 and 54), which express
levels of Faf1-myc 50% (clones 22, 44) and 100%
(clone 54) higher than control ETNA cells (Fig. 2A).
We did not obtain a higher magnitude of Faf1
expression either by transient or by stable over-
expression, as already tested by others in a different
cell system [1].
Western blot analysis of total cell lysates as well as
cytosolic and nuclear fractions showed that Faf1 is
expressed at high level in both samples (Fig. 2B).
Moreover, it is notable that the Faf1-over-expressing
clone 54 maintained the onefold increase of Faf1,
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described above, both in the nuclear and in the
cytosolic fraction (Fig. 2B).
Since Faf1 has been described as potentiating Fas/
CD95-induced apoptosis in murine L-cells and in
BOSC23 cells when over-expressed [1, 3], we treated
Faf1 over-expressing ETNAcells (clones 22, 44, 54) by
the anti-Fas antibody, which mimics Fas-ligand-driven
effects, and we tested occurrence of apoptosis by
analyzing the caspase-3 activation and cleavage of
poly-ADP ribose polymerase (PARP), two hallmarks
of caspase-dependent cell death. Apoptotic markers
were not observed in control ETNA cells or in Faf1
over-expressing clones, even though both of them
exhibit Fas/CD95 expression (Fig. 2C). By contrast,
upon induction of apoptosis via the mitochondrial
pathway by STS [15], we detected a general increase in
the level of cleaved caspase-3 and cleaved PARP after
19 h of treatment when compared to the control
ETNA cells, with clone 54 being the most responsive
(Fig. 2D). This phenomenon was confirmed in the
same clone after 48 h of treatment with CDDP, in
which the increase of cleaved caspase-3 was detected
in a dose-dependent manner (Fig. 2E). To confirm
these data, we performed fluorimetric analysis of
caspase-3 activity, which showed a remarkable in-
crease after CDDP and STS treatment (Fig. 2F).
These findings suggest that, in neural precursor cells
of telencephalic origin, Faf1 over-expression poten-
tiates apoptosis in a Fas/CD95-independent manner.
Faf1 is degraded by an apoptosome-dependent mech-
anism. We detected a considerable decrease in the
Faf1 protein level both in Faf1 over-expressing and in
control ETNA cells after apoptosis induction by STS
and CDDP treatments (Fig. 3A). Depending on the
presence of four putative caspase-cleavage sites
(DXXD) along the Faf1 protein sequence, Faf1 may
in principle be considered as a possible caspase
substrate. When we induced apoptosis with STS and
then treated these cells with the pan-caspase inhibitor
zVAD-fmk, Faf1 protein levels were rescued up to
reach values similar to those observed in untreated
cells (Fig. 3B). By contrast, in ETNA cells defective in
the Apaf1 gene (deriving from Apaf1–/– embryos,
named ETNA–/–) and therefore not displaying apop-
tosome formation, we were not able to detect Faf1
decrease after apoptosis induction (Fig. 3C). To de-
termine whether Faf1 decrease was mediated by
caspase cleavage, we mutated the four putative
cleavage sites of caspases along the Faf1 protein
sequence by site-directed mutagenesis (Asp151,
Asp294, Asp297 and Asp496 to Asn). We then trans-
fected ETNA cells with these four mutants (D151N,
D294N, D297N and D496N, respectively) and eval-
uated the Faf1 protein level after STS treatment by
Western blot analysis (Fig. 3D). No significant differ-
ence between ETNA cells transfected with the
cleavage site mutant constructs and the wild-type
construct was detected, suggesting that, although Faf1
decrease is dependent on apoptosome-activated cas-
pases, Faf1 could not be considered as a direct
substrate of caspases.
Faf1 down-regulation protects cells from death stim-
uli. Since Faf1-deficient mice displayed embryonic
lethality very early during development (see above),
we decided to study the effect of Faf1 silencing in
ETNA cells by means of small interference RNAs
(siFaf1). First, we attempted to down-regulate Faf1 in
ETNA cells by stable transfection of Faf1 interference
RNA constructs, but we were not able to find any
survivingFaf1-deficient clone (data not shown). Then,
we transiently transfected siFaf1 into ETNA cells and
we analyzed the decrease of Faf1 mRNA levels
compared to GAPDH, used as a control, by quanti-
tative real-time PCR and Northern blot analysis
(Fig. 4A, B). In transiently transfected ETNA cells
we reported a clear decrease of Faf1mRNA of about
60%; by contrast, the level of Faf1 protein only
decreases of about 20% (Fig. 4B), as revealed by
Western blot analysis. Next, we set out to verify the
cause of this protein stability. Treatment of ETNA
cells with cycloheximide, an inhibitor of protein
synthesis, demonstrated that Faf1 is very stable in
ETNA cells (Fig. 4C). However, when we treated
Faf1-down-regulated ETNA cells by apoptotic stim-
uli, such as STS, we observed a slight, although
statistical significant decrease in caspase-3 activity
(Fig. 4D), suggesting that even a slight decrease of
Faf1 could in any case protect the cell against cell
death.
To confirm this effect in an ex vivo embryonic brain
model, we took advantage of the heterozygous mice
embryos expressing ~50% of Faf1 compared to wild-
type mice (fig. 4E, insert). e12.5 Faf1+/gt and wild-type
brains were dissected. The cortical hemispheres were
placed in culture and exposed to STS. We harvested
the samples after 2 and 4 h of treatment and then we
assayed caspase-3 activity (Fig. 4E). Cortical samples
from either Faf1 heterozygous and wild-type embryos
showed comparable basal activities when assayed at
the beginning of the culture, before STS addition.
However, cortices from the heterozygous embryos
consistent with the data from siRNA- and STS-treated
ETNA cells, showed a substantial reduction in cas-
pase-3 activity at all sampling times. For example,
after 2 and 4 h of STS incubation, caspase-3 activation
was reduced by about 20% and 30%, respectively, in
cortices harvested fromFaf1 heterozygous embryos as
opposed to cortices from the wild-type controls
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(p<0.05, n=5 pairs) (Fig. 4E). Therefore, we can
conclude that Faf1 haploinsufficiency can protect
cells from cell death after pro-apoptotic stimulus.
Discussion
In the presentwork,we have demonstrated thatFaf1 is
dynamically expressed in specific areas of the mouse
developing brain. Owing to the use of different
techniques, the localization of Faf1 mRNA and b-
galactosidase protein overlap significantly, with the
former more diffuse than the latter. This observation
could be easily explained by the different molecules
analyzed, mRNA (for Faf1) and protein (for LacZ),
which could be differently confined in the various
brain regions, according to their stability or to
regulative issues (e.g., translational controls). More-
over, it could be considered that the X-gal staining is
less sensitive compared to the in situ mRNA hybrid-
ization and, in the first case, a larger mRNA amount is
needed to produce an appreciable signal.
Faf1 appears to be crucial for the development of the
whole embryo at very early stages: in fact, the Faf1-
knockout mouse dies around the two-cell stage [21].
However, it is intriguing that Faf1, as it passes through
Figure 2. Faf1 over-expression in ETNAcells. (A) ETNAcells were stably transfected with pcDNA3.1/myc-his expressing Faf1-myc fusion
protein. Clones 22, 44 and 54 were selected and the level of Faf1 protein in these clones and in control ETNA cells (ctr) was evaluated by
Western blot using anti-Faf1 antibody. (B) Total (tot), cytosolic (cyt) and nuclear (nucl) fractions from clone 54 and control ETNA cells
(ctr) were subjected to SDS-PAGE and analyzed for Faf1 distribution. Pax6 and SOD1 were used as loading and purity control of the
nuclear and cytosolic fractions, respectively. (C) Total cell lysates from clones 22, 44, 54 and control ETNA cells (ctr), treated with 1 mg/ml
anti-Fas antibody for 48 h, were subjected to SDS-PAGE and analyzed for caspase-3 expression, PARP processing and for Fas/CD95
expression. (D) Total cell lysates from clones 22, 44, 54 and control ETNA cells (ctr), treated with 5 mMstaurosporine (STS) for 19 h, were
subjected to SDS-PAGE and analyzed for caspase-3 and PARP processing. (E) Total cell lysates from clone 54 and control ETNA cells
(ctr), untreated (-) or treated with 5, 10 and 20 mM cisplatin (CDDP) for 48 h, were subjected to SDS-PAGE and analyzed for caspase-3
processing. b-Tubulin was used as a loading control. Immunoblots reported are from one experiment representative of three that gave
similar results. The density of immunoreactive bandswas calculated using the softwareAlphaEaseFC (Alpha-Innotech), normalized for b-
tubulin and reported as arbitrary units (a.u.). (F) Clone 54 and control ETNAcells (ctr), untreated or treatedwith 10 mMCDDP for 48 h or
with 5 mMSTS for 6 h, were assayed for caspase-3 activity. Caspase-3 activity is expressed as treated/untreated ratio. Results are shown as
the mean  SD; n=3, * p0.05, ** p0.01.
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the following embryonic stages, is predominantly
expressed in the developing brain, suggesting a
specific role for this protein in the regulation of
brain development. During early embryogenesis,
approximately 50–70% of the neural cells die through
apoptosis. This death is required for morphogenetic
processes involved in development and for eliminat-
ing excess cells [9–13]. Apoptosis engages the neural
precursor cells, which proliferate in the ventricular
zone of the neural tube and give rise to neurons and
glia cells, and to the postmitotic neuroblasts. Neuro-
blasts, in turn, undergo differentiation and migrate,
principally supported by glia, to the external layers of
the neural tube [22]. Neurons that have failed to
establish synaptic connections with target fields or
have producedworthless synapses, are also eliminated
by apoptosis [23]. Therefore, the fact that studies from
other laboratories have demonstrated Faf1 as a pro-
apoptotic factor and our findings about its specific
expression in developing brain lead us to suppose that
Faf1 might be a regulator of apoptosis, playing such a
role in those neural precursor cells and postmitotic
neuroblasts that populate the developing brain.
The lack of viable Faf1–/– mice to study the phenotype
in Faf1-deficient developing brain confined our anal-
ysis to a cellular model (ETNA cells), which repre-
sents a bona fide neural precursor cell system. In fact,
this neural cell line derives from the telencephalon of
the developing brain, characterized by high and
specific expression of Faf1.
Analysis of Faf1 over-expression in ETNA cells and of
its down-regulation both in ETNA cells and in
Figure 3.Caspase-dependent Faf1 decrease. (A) Total cell lysates from clone 54 and control ETNA cells (ctr), untreated (-) or treated with
5 mM STS for 19 h and 24 h or with 10 mM CDDP for 48 h, were subjected to SDS-PAGE and analyzed for Faf1 protein level. The single
asterisk indicates themyc-tagged Faf1. (B) Total cell lysates from clone 54 and control ETNAcells (ctr), untreated (-) or treated with 5 mM
STS for 19 h (+) and with 5 mMSTS for 19 h in the presence of the pan-caspase inhibitor zVAD-fmk (100mM) (+), were subjected to SDS-
PAGE and analyzed for caspase-3 processing and Faf1 protein level. (C) Total cell lysates from the apoptosome-deficient ETNA–/– cells,
were untreated (-) or treatedwith 5 mMSTS for 19 h (+). Theywere then analyzed for Faf1 protein level. (D) Total cell lysates fromETNA
cells, transfected with pcDNA3.1 as control (ctr), pcDNA3.1-Faf1 (Faf1), and the four Faf1 mutants (D151N, D294N, D297N andD496N),
were untreated (-) or treated with 5 mMSTS for 19 h (+), subjected to SDS-PAGE and analyzed for Faf1 protein level. b-Tubulin was used
as loading control. Immunoblots reported are from one experiment representative of three that gave similar results. Density of
immunoreactive bands was calculated using the software AlphaEaseFC, normalized for b-tubulin and reported as arbitrary units (a.u.).
Results are shown as the mean  SD; n=3, * p0.05, ** p0.01.
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Figure 4. Faf1 down-regulation protects from STS-dependent apoptosis. (A) ETNA cells were transiently transfected with siRNA duplex
against the Faf1 mRNA target sequence (siFaf1) or against the GAPDHmRNA target sequence (siGAPDH). The mRNA levels of Faf1
andGAPDHwere evaluated in each transfection by quantitative real-time PCR and are presented as arbitrary units (a.u.) with respect to
actin, used as control. (B) Transiently transfected ETNA cells with a scrambled siRNA duplex (-) or siFaf1 (+) were assayed for Faf1
mRNA and protein level by Northern blot (N.B.) andWestern blot (W.B.), respectively. The 500-bp fragment of Faf1 cDNA as radioactive
probe and anti-Faf1 antibody were used in Northern and Western blot analyses, respectively. GAPDH was used as loading control.
Northern and Western blots reported are from one experiment representative of three that gave similar results. Densitometric analyses
were calculated using the softwareAlphaEaseFC, normalized forGAPDHand reported as a.u. (C) ETNAcells were treatedwith different
concentrations of cycloheximide (CHX; 10, 20, 50 mg/ml) for 24 and 48 h and total cell lysates were analyzed for Faf1 protein level. b-
Tubulin was used as loading control. Immunoblots reported are from one experiment representative of three that gave similar results.
Density of immunoreactive bands was calculated using the software AlphaEaseFC, normalized for b-tubulin and reported as a.u. (D)
Transiently transfected ETNA cells with a scrambled siRNA duplex (-) or with siRNA duplex against Faf1 (siFaf1), both untreated and
treated with 5 mM STS for 6 h, were assayed for caspase-3 activity, expressed as treated/untreated ratio. Results are shown as the mean
SD; n=3, * p0.05, ** p0.01. (E) e12.5 embryonic brains from wild-type and Faf1+/gt embryos were dissected. Cortices were placed in
culture and apoptosis was induced by 10 mM STS. After incubation for 2 and 4 h, the samples were harvested and caspase-3 activity was
assayed. Data from five pairs of embryos are presented as themean SD. The columns report the relative percentage of caspase-3 activity
of Faf1 haploinsufficient embryonic hemispheres versus wild-type samples. Faf1 protein levels in Faf1+/gt and wild-type brain of pn1 mice
were analysed byWestern blot in order to confirm the reduction of Faf1 in Faf1+/gt vs. wild-type littermates (see insert). Actin was used as
loading control.
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embryonic brain explants, has provided us with a
helpful tool for investigating Faf1s function. Faf1-
enhanced apoptosis does not occur upon Fas/CD95
induction in the ETNA proneural cell line, but takes
place only following apoptotic stimuli such as STS and
CDDP, which induce apoptosis through themitochon-
drial/apoptosome pathway. It is well known that the
mitochondrial death route is the most important
pathway involved in the regulation of apoptosis during
neurodevelopment [9]. Hence, the fact that Faf1 is
expressed at high concentrations in certain regions of
the brain and that it enhances apoptosis through the
mitochondrial/apoptosome pathway in neural precur-
sor cells, may suggest the role of Faf1 as a pro-
apoptotic factor in regulating brain development.
Moreover, the findings that either a slight (in siFaf1-
treated ETNA cells) or a consistent (in Faf1+/gt
embryonic brains) reduction of Faf1 down-regulates
drug-induced caspase-3 activity, further confirm
Faf1s pro-apoptotic role in developing brain.
We also observed that, after cell death induction, Faf1
itself decreases in a caspase-dependent manner via
apoptosome formation. In this context, the experi-
ments performed in ETNA–/– cells have allowed us to
demonstrate the specific involvement of the apopto-
some in this degradation. Although Faf1 contains four
putative caspase cleavage sites, their site-directed
mutagenesis did not rescue Faf1 protein levels,
suggesting that Faf1 is not a direct substrate of
caspases. Thus, we speculate that intermediate factors
between caspases and Faf1 need to be taken into
consideration. In addition, the fact that Faf1 poten-
tiates the caspase-3 activity and is itself degraded in a
caspase-dependent manner after apoptotic stimuli
may suggest that a negative feedback could regulate
Faf1 levels. This being the case, the concentration of
the “pro-apoptotic” form of Faf1 would decrease
during apoptosis, thus modulating the intensity of the
cell death phenomenon, at least during brain develop-
ment.
Our results in modulating Faf1 expression indicate
that Faf1 is a cell death “enhancer” more than an
“effector”, and a dramatic modulation of Faf1 protein
is not possible since Faf1 seems to be a very stable
protein and its silencing by the siRNA technique does
not lead to a consistent decrease of protein levels. The
heterozygous embryos, which express only 50%of the
standard amount of Faf1 protein, are phenotypically
indistinguishable from thewild-type littermates.How-
ever, when we induce apoptosis in developing cortical
hemispheres, we observe caspase-3 reduction due to
Faf1 haploinsufficiency. This suggests that the amount
of Faf1 needs to be maintained within a certain range
to ensure its function. Nevertheless, to gain a better
understanding of Faf1 function in developing brain, a
conditional transgenic mouse model that can over-
express or lack Faf1 only in specific neural cell
populations must be considered, given the premature
death of Faf1-knockout clones together with the early
embryonic lethality of Faf1–/– mice.
It should be mentioned that preliminary studies on
Alzheimers disease using cDNA microarrays [24]
have demonstrated that human FAF1 is strongly up-
regulated in pathological conditions, as revealed by
the gene expression profile made on brain tissue
samples from Alzheimer patients. This also implies a
key role for FAF1 in brain homeostasis. In addition, a
FAF1 modulating function on mineral corticoid
receptor-mediated transcription in hippocampal cells
seems to confirm a neural function for this factor [25].
Unraveling Faf1s role in the control of neural cells
development and physiology may thus be of great
interest to biomedicine.
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